Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors: A progress review

E. G. Macewen, I. D. Kurzman, S. Helfand, D. Vail, C. London, W. Kisseberth, R. C. Rosenthal, L. E. Fox, E. T. Keller, J. Obradovich, B. Madewell, C. Rodriguez, B. Kitchell, J. Fidel, S. Susaneck, M. Rosenberg

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Targeted delivery of macrophage activating agents is an attractive approach to treat micrometastatic disease. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) is a potent activator of monocytes/macrophages in humans, mice, and dogs. We have conducted clinical trials in dogs with malignant and highly metastatic spontaneous tumors. Presented are results of our trials evaluating L-MTP-PE in combination with surgery and chemotherapy in dogs with spontaneous osteosarcoma and hemangiosarcoma, particularly relevant malignancies having many similarities to human cancer. Osteosarcoma dogs received chemotherapy following surgery (cisplatin q 28 days × 4). At completion of chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.021). Dogs with splenic hemangiosarcoma received combination chemotherapy following surgery (doxorubicin and cyclophosphamide q 21 days × 4). At the first chemotherapy, dogs were randomized to receive L-MTP-PE or placebo. The L-MTP-PE group had a significantly longer median survival time compared to the placebo group (p < 0.03). These studies show that L-MTP-PE is an effective agent for treatment of metastasis and can be safely administered in combination with chemotherapy.

Original languageEnglish (US)
Pages (from-to)391-396
Number of pages6
JournalJournal of Drug Targeting
Volume2
Issue number5
DOIs
StatePublished - 1994

Keywords

  • Canine
  • Hemangiosarcoma
  • Immunotherapy
  • Liposome
  • Muramyl tripeptide
  • Osteosarcoma

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors: A progress review'. Together they form a unique fingerprint.

  • Cite this

    Macewen, E. G., Kurzman, I. D., Helfand, S., Vail, D., London, C., Kisseberth, W., Rosenthal, R. C., Fox, L. E., Keller, E. T., Obradovich, J., Madewell, B., Rodriguez, C., Kitchell, B., Fidel, J., Susaneck, S., & Rosenberg, M. (1994). Current studies of liposome muramyl tripeptide (CGP 19835a lipid) therapy for metastasis in spontaneous tumors: A progress review. Journal of Drug Targeting, 2(5), 391-396. https://doi.org/10.3109/10611869408996814